Delivery Order SPE2DR25D2104-SPE2DR26F3RDC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,615.59 to AmerisourceBergen Drug Corp for Xhance 93 microgram nasal spray (16 milliliters) on October 30, 2025. This firm fixed-price delivery order, with an ultimate completion date of October 31, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Xhance 93 microgram nasal spray in 16-milliliter units. This is a firm fixed-price contract with a ceiling value of $1,241.25 and an ultimate completion date of November 12, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $4,547.56 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for Xhance 93 microgram nasal spray (16 milliliters). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $16,843.25 delivery order to AmerisourceBergen Drug Corp for Xhance 93 mcg nasal spray (16 mL) on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for Xhance 93 micrograms nasal spray (16 milliliters) with a ceiling value of $3,221.73. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of November 5, 2025, and performance at the vendor's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,134.11 to supply Xhance 93 MCG nasal spray (16 mL units) with an ultimate completion date of September 18, 2025. This non-competitive delivery order utilizes firm fixed pricing and was awarded on September 17, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $4,033.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XHANCE 93 micrograms nasal spray (16 milliliters) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside award was issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $16,960.28 to AmerisourceBergen Drug Corp for XHANCE 93 MCG Nasal Spray (16ML) on November 12, 2025, with an ultimate completion date of November 13, 2025. This competitively awarded, firm fixed price contract utilizes no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $1,724.52 to AmerisourceBergen Drug Corp for Xhance 93 mcg nasal spray (16mL) on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xhance 93 microgram nasal spray in 16-milliliter units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing with a ceiling value of $3,180.19 and an ultimate completion date of August 14, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3RDCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,734.74 to AmerisourceBergen Drug Corp for Xhance 93 mcg nasal spray (16 ml) on December 10, 2025, with an ultimate completion date of December 11, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract falls within AmerisourceBergen's comprehensive global pharmaceutical support vehicle, which enables the company to supply a broad range of medications, medical supplies, and healthcare commodities to support military healthcare programs worldwide. Xhance is a prescription nasal spray used in the treatment of nasal polyps, reflecting the company's role in supplying specialized pharmaceutical products to the Defense Health Agency and other federal healthcare systems. This delivery order exemplifies AmerisourceBergen's established capability to fulfill federal medical procurement requirements through DLA's strategic pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 12/9/25 |